Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NTRA Natera, Inc.

交易中 08-14 14:37:41 EDT

310.69

-0.09

-0.03%

最高311.99	最低305.00	成交量85.50万
今开308.01	昨收310.78	日振幅2.25%
总市值444.96亿	流通市值431.86亿	总股本1.43亿
成交额2.65亿	换手率0.62%	流通股本1.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NTRA","market":"US","secType":"STK","nameCN":"Natera, Inc.","latestPrice":310.69,"timestamp":1786732660820,"preClose":310.78,"halted":0,"volume":854964,"delay":0,"changeRate":-0.0002895939249629159,"floatShares":139000000,"shares":143215382,"eps":-1.372894,"marketStatus":"交易中","change":-0.09,"latestTime":"08-14 14:37:41 EDT","open":308.01,"high":311.99,"low":305,"amount":264640708.91412002,"amplitude":0.022492,"askPrice":310.94,"askSize":15,"bidPrice":310.45,"bidSize":239,"shortable":3,"etf":0,"ttmEps":-1.372894,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1435809600000,"exchange":"NASDAQ","adjPreClose":310.78,"preHourTrading":{"tag":"盘前","latestPrice":308.33,"preClose":310.78,"latestTime":"09:29 EDT","volume":267,"amount":82232.88678,"timestamp":1786714199999,"change":-2.45,"changeRate":-0.007883,"amplitude":0.013997},"postHourTrading":{"tag":"盘后","latestPrice":311.09,"preClose":310.78,"latestTime":"19:34 EDT","volume":213053,"amount":66212917.8761,"timestamp":1786664048318,"change":0.31,"changeRate":0.000997,"amplitude":0.000997},"volumeRatio":0.564031,"impliedVol":0.4602,"impliedVolPercentile":0.4303},"requestUrl":"/m/hq/s/NTRA","defaultTab":"news","newsList":[{"id":"1172077351","title":"Natera助力新临床研究：利用Latitude™评估晚期皮肤癌ctDNA动态变化","url":"https://stock-news.laohu8.com/highlight/detail?id=1172077351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172077351?lang=zh_cn&edition=full","pubTime":"2026-08-12 18:02","pubTimestamp":1786528935,"startTime":"0","endTime":"0","summary":"Natera将支持一项全新临床试验，旨在评估Latitude™技术在晚期皮肤癌中监测循环肿瘤DNA（ctDNA）动态变化的能力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0053671581.USD","LU1988902786.USD","LU2065731478.USD","LU2264538146.SGD","LU2065169927.USD","LU2065171402.SGD","LU0012050646.USD","GNOM","LU0345770308.USD","BK4139","NTRA","LU2324357040.USD","HELX","LU0106261612.USD","LU0345770993.USD","LU2065171311.SGD","LU0963586101.USD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148194782","title":"异动解读｜Natera盘中上涨19.24%，Q2营收大超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1148194782","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148194782?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:42","pubTimestamp":1786110134,"startTime":"0","endTime":"0","summary":"8月7日，Natera盘中上涨19.24%，报316.0美元/股，成交额1.11亿美元。消息面上，公司发布Q2财报，营收7.528亿美元，同比增长37.7%，大幅超出市场一致预期的6.61亿美元；调整后每股亏损0.47美元，优于预期的0.49美元。同时，公司将全年营收指引上调至28.5亿至29.1亿美元，高于此前的27.4亿至28.2亿美元及市场预期的28.0亿美元。此外，RBC Capital将目标价从275美元上调至350美元，维持\"跑赢大盘\"评级。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Natera盘中上涨19.24%，Q2营收大超预期叠加全年指引上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122596166","title":"异动解读｜Natera盘前上涨13.42%，Q2营收大超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1122596166","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122596166?lang=zh_cn&edition=full","pubTime":"2026-08-07 19:15","pubTimestamp":1786101307,"startTime":"0","endTime":"0","summary":"8月7日，Natera盘前上涨13.42%，报300.94美元/股。消息面上，公司盘后发布Q2财报，营收7.528亿美元，同比增长37.7%，大幅超出市场一致预期的6.61亿美元；调整后每股亏损0.47美元，优于预期的0.49美元，同比改善36.5%。同时，公司将全年营收指引上调至28.5亿至29.1亿美元，高于此前的27.4亿至28.2亿美元及市场预期的28.0亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Natera盘前上涨13.42%，Q2营收大超预期叠加全年指引上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160367193","title":"异动解读 | 财报发布叠加多重利好，Natera夜盘大涨13.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=1160367193","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160367193?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:15","pubTimestamp":1786061729,"startTime":"0","endTime":"0","summary":"Natera, Inc.今日夜盘交易中股价大涨13.05%，引发市场广泛关注。消息面上，公司于盘后发布了最新季度财报。此前市场一致预期本季度营收为6.61亿美元，同比增长38.72%，调整后每股亏损0.49美元。此外，公司核心产品Signatera近期接连获得欧盟IVDR认证、日本PMDA批准及美国NCCN一类推荐，同时与Aveta Biomics、Eledon等多家生物医药公司达成三期临床合作，持续巩固其在MRD检测领域的领导地位。这些积极进展进一步提振了市场信心，推动股价夜盘大幅走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170499782","title":"异动解读｜Natera夜盘上涨13.05%，Q2财报大幅超预期叠加全年指引上调","url":"https://stock-news.laohu8.com/highlight/detail?id=1170499782","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170499782?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:15","pubTimestamp":1786061714,"startTime":"0","endTime":"0","summary":"8月7日，Natera夜盘上涨13.05%，报300.01美元/股，成交额3000.0美元。消息面上，公司盘后发布Q2财报，营收7.528亿美元，同比增长37.7%，大幅超出市场一致预期的6.61亿美元；调整后每股亏损0.47美元，优于预期的0.49美元，同比改善36.5%。同时，公司将全年营收指引上调至28.5亿至29.1亿美元，高于此前的27.4亿至28.2亿美元及市场预期的28.0亿美元。Natera是一家诊断公司，拥有专有的分子和生物信息技术，目标是使个性化基因检测成为护理标准的一部分。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Natera夜盘上涨13.05%，Q2财报大幅超预期叠加全年指引上调","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135983314","title":"异动解读 | 财报发布叠加多重利好，Natera盘后大涨16.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=1135983314","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1135983314?lang=zh_cn&edition=full","pubTime":"2026-08-07 04:36","pubTimestamp":1786048586,"startTime":"0","endTime":"0","summary":"Natera, Inc.今日盘后股价大涨16.47%，引发市场广泛关注。消息面上，公司于盘后发布了最新季度财报。此前市场一致预期本季度营收为6.61亿美元，同比增长38.72%，调整后每股亏损0.49美元。此外，公司核心产品Signatera近期接连获得欧盟IVDR认证、日本PMDA批准及美国NCCN一类推荐，同时与Aveta Biomics、Eledon等多家生物医药公司达成三期临床合作，持续巩固其在MRD检测领域的领导地位。这些积极进展进一步提振了市场信心，推动股价盘后大幅走高。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191517672","title":"异动解读｜Natera盘后上涨8.15%，财报发布后市场反应积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1191517672","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191517672?lang=zh_cn&edition=full","pubTime":"2026-08-07 04:08","pubTimestamp":1786046880,"startTime":"0","endTime":"0","summary":"8月7日，Natera盘后上涨8.15%，报288.49美元/股，成交额2227.51万美元。消息面上，公司于8月6日盘后发布最新季度财报。此前市场一致预期本季度营收为6.61亿美元，同比增长38.72%，调整后每股亏损0.49美元。近期公司核心产品Signatera接连获得欧盟IVDR认证、日本PMDA批准及NCCN一类推荐，同时与Aveta Biomics、Eledon等达成多项三期临床合作，持续巩固MRD检测领域领导地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113645994","title":"异动解读｜Natera盘中上涨5.08%，财报前瞻强劲叠加Signatera多项利好催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1113645994","media":"行情直击","labels":["preview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113645994?lang=zh_cn&edition=full","pubTime":"2026-07-31 01:31","pubTimestamp":1785432704,"startTime":"0","endTime":"0","summary":"7月31日，Natera盘中上涨5.08%，报266.715美元/股，成交额1.43亿美元。消息面上，公司将于8月6日发布季度财报，市场一致预期本季度营收约6.61亿美元，同比增长38.72%，调整后每股亏损收窄至-0.49美元，同比改善19.84%。近期催化密集：7月Signatera获得欧盟IVDR Class C认证，覆盖多种实体瘤类型，支持欧盟商业化延续至2028年后；同月发表的JAMA Dermatology研究显示Signatera在默克尔细胞癌复发预测中灵敏度达90%，显著优于现有标准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182330355","title":"财报前瞻｜Natera, Inc.本季度营收预计增38.72%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1182330355","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182330355?lang=zh_cn&edition=full","pubTime":"2026-07-31 00:05","pubTimestamp":1785427525,"startTime":"0","endTime":"0","summary":"Natera, Inc.将于2026年08月06日发布最新季度财报，市场关注营收延续高增长与盈利改善节奏。市场一致预期本季度Natera, Inc.营收为6.61亿美元，同比增38.72%；毛利率预测数据未披露；净利润或净利率预测数据未披露；调整后每股收益为-0.49美元，同比改善19.84%。上季度Natera, Inc.营收6.97亿美元，同比增长38.82%；毛利率64.71%；归属于母公司股东的净利润为-8,509.10万美元，净利率为-12.21%；调整后每股收益为-0.60美元，同比改善20.00%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Natera, Inc.本季度营收预计增38.72%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010113","title":"错峰抄底重仓特斯拉 木头姐ARK Invest完成全品类持仓调仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010113","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654010113?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:12","pubTimestamp":1785154356,"startTime":"0","endTime":"0","summary":"金吾财讯｜凯茜·伍德旗下ARK Invest完成大规模双向调仓操作，整体延续聚焦AI、自动驾驶、太空科技、创新医疗、金融科技的核心投资主线，在多赛道加码优质标的，同时对部分科技、工业、医疗标的获利减持，持仓结构进一步优化。本期最大手笔增持为特斯拉，在特斯拉二季度财报不及预期、单日暴跌约15%创下一年最大单日跌幅后，ARK Invest逆势加仓价值5270万美元的特斯拉股票。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303054","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDL","TEM","TSLA","HOOD","LTL","BULZ","ARKK","ROKU","META","ARKX","ATAI","SHPD","AMD","ARKG","TSLL","ILMN","ESLT","NTRA","SMH","ARKW","MAGY","CRCL","YMAG","IXJ","PRME","VEGI","SNOW","SHOP","TER","SARK","FIG","BIDU","CDNA","SRTA","IRDM","SCTX","LLY","ARKQ","TWST","DE","CAT","ARKF","TXG","ABSI","ARKB","XE","ACHR","CMPS","OGIG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1138442146","title":"“木头姐”再度调整持仓，加码Meta、减持AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=1138442146","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138442146?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:38","pubTimestamp":1783694306,"startTime":"0","endTime":"0","summary":"方舟投资创始人兼首席投资官Cathie Wood周四继续调整投资组合，大举加仓 $Meta Platforms, Inc.$，同时进一步减持芯片巨头 $美国超微公司$。这也是Meta将于7月29日公布第二季度业绩前的重要布局。此外，Meta近期持续加码AI业务，不仅推出首个付费AI模型，还宣布自研AI芯片将于9月进入量产阶段。与此同时，ARK继续减持AMD，合计卖出10774股，套现约560万美元。市场分析认为，此次减持更可能是获利了结及投资组合再平衡，并不代表ARK看空AMD的基本面。","market":"us","thumbnail":"https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0fb0479ff67cd3a760cdce353bcb60ed"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HOOD","HOOY","HOOZ","FBYY","AMDW","DAMD","IONS","HOOW","CCUP","META","AMDG","METD","AMD","AMDL","HOOI","CRCG","HOYY","HOOG","CRCL","AMYY","HODU","ROKU","NTRA","AMDD","FBL","HOOX","ICRC","CRCO","METU","CRCD","AMDU","HOII","ROBN","AMUU","METW","AMDY","CRCA","FBY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1138346939","title":"异动解读｜Natera盘后下跌5.1%，报270.33美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138346939","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138346939?lang=zh_cn&edition=full","pubTime":"2026-07-01 04:03","pubTimestamp":1782849827,"startTime":"0","endTime":"0","summary":"7月1日，Natera盘后下跌5.1%，报270.33美元/股，成交额351.95万美元。Natera所在的生物科技行业中，个股中，Abivax S.A.涨0.03%，艾伯维公司涨0%，吉利德科学涨0%，福泰制药涨0%，安进涨0%。Natera是一家诊断公司，拥有专有的分子和生物信息技术，应用于改变全球范围内的疾病管理。公司的无细胞DNA技术结合新颖的分子分析方法，以高精度识别涵盖广泛严重疾病的遗传变异，目标是使个性化基因检测成为护理标准的一部分。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149807344","title":"Natera与Aveta Biomics达成战略合作，共同推进Apg-157治疗头颈癌的全球三期注册试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1149807344","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149807344?lang=zh_cn&edition=full","pubTime":"2026-06-29 18:02","pubTimestamp":1782727371,"startTime":"0","endTime":"0","summary":"Natera与Aveta Biomics宣布建立战略合作伙伴关系，双方将携手支持Apg-157用于治疗头颈癌的全球三期注册临床试验。此次合作旨在加速该候选药物的临床开发进程，以期满足该疾病领域未满足的医疗需求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0053671581.USD","LU2324357040.USD","LU0963586101.USD","BK4139","LU0106261612.USD","LU0345770993.USD","LU0012050646.USD","LU0345770308.USD","NTRA","LU1064131342.USD","LU2065170008.USD","LU2065171402.SGD","LU2065731478.USD","LU2065169927.USD","LU2264538146.SGD","LU1988902786.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194638255","title":"Natera与Eledon宣布在计划的三期肾脏移植试验中就Prospera™监测达成战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1194638255","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194638255?lang=zh_cn&edition=full","pubTime":"2026-06-25 19:02","pubTimestamp":1782385353,"startTime":"0","endTime":"0","summary":"Natera与Eledon Pharmaceuticals宣布，双方已就一项战略合作伙伴关系达成一致，将在Eledon计划开展的第三期肾脏移植临床试验中，整合并应用Natera的Prospera™移植排斥监测技术。\n此次合作旨在评估Prospera™在监测接受Eledon实验性疗法治疗的肾移植患者中的效用。该合作将专注于推进移植领域的精准医疗，通过无创检测方法，力求更早、更准确地识别移植排斥反应，从而有望改善患者的长期预后。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0345770308.USD","ELDN","LU0053671581.USD","LU0345770993.USD","NTRA","LU0106261612.USD","LU2065171402.SGD","LU2065731478.USD","LU2065170008.USD","LU1064131342.USD","LU2065169927.USD","LU2264538146.SGD","LU2065171311.SGD","LU1988902786.USD","BK4139","LU0012050646.USD","LU2324357040.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131089167","title":"异动解读｜Natera盘中上涨9.14%，Signatera检测产品获日本监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1131089167","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131089167?lang=zh_cn&edition=full","pubTime":"2026-06-25 00:12","pubTimestamp":1782317568,"startTime":"0","endTime":"0","summary":"6月24日，Natera盘中上涨9.14%，报256.215美元/股，成交额2.77亿美元。消息面上，Natera旗下分子微小残留病灶检测产品Signatera获得日本药品和医疗器械管理局监管批准，用于结直肠癌患者的术后辅助治疗决策指导。Signatera由此成为日本首个且唯一获官方批准的MRD检测工具。该批准基于Galaxy临床试验数据，结果显示化疗对术后MRD阳性患者有获益，而对MRD阴性患者无显著效果。Natera表示，Signatera预计于年底前在日本市场正式商业化推出，具体时间取决于医保报销审批及最终定价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645891941","title":"Natera(NTRA)癌症微小残留病灶检测产品Signatera™获日本PMDA监管批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2645891941","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645891941?lang=zh_cn&edition=full","pubTime":"2026-06-24 17:54","pubTimestamp":1782294841,"startTime":"0","endTime":"0","summary":"这一进程使得 Signatera 成为日本首个且唯一获得官方批准的 MRD 检测工具，将主要用于指导结直肠癌患者的术后辅助治疗决策。Natera 官方表示，Signatera 预计将于 2026 年底前正式在日本市场推出，具体的上市时间表将取决于接下来的医保报销审批及最终定价。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/YjE5NjM0NjA5NTUxNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301840","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0345770993.USD","NTRA","LU2065169927.USD","LU0012050646.USD","LU0345770308.USD","LU0106261612.USD","LU0963586101.USD","LU2065170008.USD","LU1064131342.USD","LU2065171402.SGD","LU2264538146.SGD","LU2324357040.USD","BK4139","LU0053671581.USD","LU1988902786.USD","LU2065731478.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182423510","title":"异动解读｜Natera盘中上涨5.5%，Signatera检测平台接连斩获临床合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1182423510","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1182423510?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:36","pubTimestamp":1780583761,"startTime":"0","endTime":"0","summary":"6月4日，Natera盘中上涨5.5%，报224.995美元/股，成交额4695.66万美元。消息面上，Natera近期接连获得重要临床进展。此外，公司还宣布已在一项评估MRD指导早期乳腺癌治疗决策的研究中完成首批患者入组，该研究计划在美国50个中心招募约725名患者，旨在通过Signatera检测减少过度治疗。上述进展进一步拓展了Signatera在肿瘤学领域的临床应用场景，强化了市场对公司核心检测平台商业化前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639621297","title":"Natera(NTRA)携手Diakonos Oncology开发用于治疗难治性黑色素瘤的Signatera™","url":"https://stock-news.laohu8.com/highlight/detail?id=2639621297","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639621297?lang=zh_cn&edition=full","pubTime":"2026-05-29 18:35","pubTimestamp":1780050915,"startTime":"0","endTime":"0","summary":"双方将联合利用Natera独家的Signatera分子检测技术，共同评估一款针对难治性黑色素瘤的创新树突状细胞疗法。根据合作协议，Natera将利用其核心的Signatera液体活检平台，对Diakonos正在进行的DOC-RM I/II期临床试验进行深度支持。据悉，难治性黑色素瘤是目前肿瘤学领域公认的“硬骨头”。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300976","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU2065731478.USD","NTRA","LU2065171402.SGD","LU1064131342.USD","LU2065170008.USD","LU0345770993.USD","LU2065169927.USD","LU0106261612.USD","BK4139","LU0012050646.USD","LU2264538146.SGD","LU0345770308.USD","LU2324357040.USD","LU2065171311.SGD","LU0053671581.USD","LU0963586101.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638351555","title":"Natera(NTRA)将推出增强型Panorama™ NIPT 持续扩大生育健康筛查市场领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2638351555","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638351555?lang=zh_cn&edition=full","pubTime":"2026-05-26 18:26","pubTimestamp":1779791191,"startTime":"0","endTime":"0","summary":"截至本文发稿，Natera市值约为 291亿美元，最新报209.23美元，盘前股价上涨2.97%，最新市值位列全球诊断与实验室医疗服务行业前列。通过提高首次检测成功率，公司不仅能大幅优化毛利率、降低运营成本，更有望进一步蚕食依赖传统计数法技术的竞争对手份额，持续扩大其在生育健康筛查市场的领先优势。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300796","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2264538146.SGD","LU2065169927.USD","LU0963586101.USD","LU0345770993.USD","LU1064131342.USD","LU2065170008.USD","LU0345770308.USD","LU1988902786.USD","LU2065731478.USD","LU0053671581.USD","LU0106261612.USD","LU2065171402.SGD","LU0012050646.USD","NTRA","LU2065171311.SGD","BK4139","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153076980","title":"FDA批准阿替利珠单抗用于部分患者肌层浸润性膀胱癌的辅助治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1153076980","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153076980?lang=zh_cn&edition=full","pubTime":"2026-05-16 00:58","pubTimestamp":1778864321,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局(FDA)已批准阿替利珠单抗用于存在分子残留病灶的肌层浸润性膀胱癌患者的辅助治疗。\n同时，FDA亦批准将Natera公司的Signatera CDX作为泰圣奇膀胱癌治疗的伴随诊断工具，适用于部分患者。\n（注：文中提及的公司代码为ROPC.S）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1064131342.USD","LU0053671581.USD","LU0012050646.USD","BK4139","LU0106261612.USD","LU0345770993.USD","LU1988902786.USD","LU2065171311.SGD","LU2065731478.USD","NTRA","LU0963586101.USD","LU2264538146.SGD","LU2324357040.USD","LU0345770308.USD","LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.natera.com","stockEarnings":[{"period":"1week","weight":0.1711},{"period":"1month","weight":0.1398},{"period":"3month","weight":0.6676},{"period":"6month","weight":0.507},{"period":"1year","weight":0.9707},{"period":"ytd","weight":0.3566}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Natera, Inc.于2007年1月在特拉华州成立。该公司是一家诊断公司，拥有专有的分子和生物信息技术，该公司正在应用该技术来改变全球范围内的疾病管理。该公司的无细胞DNA（CFDNA）技术结合了新颖的分子分析方法，这些方法可以从小到单个细胞的样本中可靠地测量整个基因组中的许多信息区域，以及统计算法，这些算法结合了更广泛的科学界提供的数据，以高精度和高覆盖率识别涵盖广泛严重疾病的遗传变异。该公司的目标是使个性化基因检测和诊断成为保护健康的护理标准的一部分，并告知更早和更有针对性的干预措施，以帮助实现更长寿、更健康的生活。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.017867},{"month":2,"riseRate":0.545455,"avgChangeRate":0.019142},{"month":3,"riseRate":0.454545,"avgChangeRate":0.002026},{"month":4,"riseRate":0.727273,"avgChangeRate":0.035796},{"month":5,"riseRate":0.818182,"avgChangeRate":0.097296},{"month":6,"riseRate":0.818182,"avgChangeRate":0.127144},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.000068},{"month":8,"riseRate":0.833333,"avgChangeRate":0.153761},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.04947},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.038241},{"month":11,"riseRate":0.545455,"avgChangeRate":0.100491},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.000753}],"exchange":"NASDAQ","name":"Natera, Inc.","nameEN":"Natera"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Natera, Inc.,NTRA,Natera, Inc.股票,Natera, Inc.股票老虎,Natera, Inc.股票老虎国际,Natera, Inc.行情,Natera, Inc.股票行情,Natera, Inc.股价,Natera, Inc.股市,Natera, Inc.股票价格,Natera, Inc.股票交易,Natera, Inc.股票购买,Natera, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Natera, Inc.(NTRA)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Natera, Inc.(NTRA)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}